个人中心| | 帮助
高级检索
当前位置： 首页 > 详情页

Randomized phase III trial of aumolertinib (HS-10296, Au) versus gefitinib (G) as first-line treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) and EGFR exon 19 del or L858R mutations (EGFRm).

| 认领 | 导出 | |

文献详情

资源类型：
WOS体系：

收录情况： ◇ SCIE ◇ CPCI(ISTP)

作者：
Lu, Shun[1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18,19,20] ; Dong, Xiaorong[1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18,19,20] ; Jian, Hong[1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18,19,20] ; Chen, Jianhua[1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18,19,20] ; Chen, Gongyan[1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18,19,20] ; Sun, Yuping[1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18,19,20] ; Ji, Yinghua[1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18,19,20] ; Wang, Ziping[1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18,19,20] ; Shi, Jianhua[1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18,19,20] ; Lu, Junguo[1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18,19,20] ; Chen, Shaoshui[1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18,19,20] ; Zhang, Guojun[1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18,19,20] ; Lv, Dongqing[1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18,19,20] ; Liu, Chunling[1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18,19,20] ; Li, Juan[1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18,19,20] ; Yu, Xinmin[1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18,19,20] ; Lin, Zhong[1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18,19,20] ; Yu, Zhuang[1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18,19,20] ; Wang, Zhehai[1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18,19,20] ; Cui, Jiuwei[1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18,19,20] ;
机构： [1]Shanghai Jiao Tong Univ, Shanghai Chest Hosp, Shanghai Lung Canc Ctr, Shanghai, Peoples R China [2]Huazhong Univ Sci & Technol, Tongji Med Coll, Union Hosp, Wuhan, Peoples R China [3]Shanghai Chest Hosp, Shanghai, Peoples R China [4]Cent South Univ, Canc Hosp, Dept Med Oncol, Changsha, Peoples R China [5]Harbin Med Univ Canc Hosp, Harbin, Peoples R China [6]Shandong First Med Univ & Shandong Acad Med Sci, Shandong Canc Hosp & Inst, Jinan, Peoples R China [7]Xinxiang Med Univ, Affiliated Hosp 1, Xinxiang, Henan, Peoples R China [8]Beijing Canc Hosp, Dept Thorac Med Oncol, Beijing, Peoples R China [9]Linyi Canc Hosp, Linyi, Shandong, Peoples R China [10]Nantong Tumor Hosp, Nantong, Peoples R China [11]Binzhou Med Coll, Affiliated Hosp, Binzhou, Peoples R China [12]Zhengzhou Univ, Affiliated Hosp 1, Zhengzhou, Peoples R China [13]Wenzhou Med Univ, Affiliated Taizhou Hosp, Lab Cellular & Mol Radiat Oncol, Radiat Oncol Inst,Enze Med Hlth Acad, Taizhou, Peoples R China [14]Xinjiang Med Univ, Affiliated Tumor Hosp, Urumqi, Peoples R China [15]Sichuan Canc Hosp, Chengdu, Peoples R China [16]Zhejiang Canc Hosp, Hangzhou, Peoples R China [17]Sun Yat Sen Univ, Dept Thorac Oncol, Affiliated Hosp 5, Zhuhai, Peoples R China [18]Qingdao Univ, Affiliated Hosp, Qingdao, Peoples R China [19]Shandong Canc Hosp & Inst, Jinan, Peoples R China [20]First Hosp Jilin Univ, Changchun, Peoples R China
出处：
DOI： 10.1200/JCO.2021.39.15_suppl.9013
ISSN：
基金：
Hansoh PharmaDexcel Pharma
语种：
外文
被引次数：
WOS：
中科院(CAS)分区：
出版当年[2021]版：
大类 | 1 区 医学
小类 | 1 区 肿瘤学
最新[2023]版：
大类 | 1 区 医学
小类 | 1 区 肿瘤学
JCR分区：
出版当年[2021]版：
Q1 ONCOLOGY
最新[2023]版：
Q1 ONCOLOGY

影响因子： 最新[2023版] 最新五年平均 出版当年[2021版] 出版当年五年平均 出版前一年[2020版] 出版后一年[2022版]

第一作者：
第一作者机构： [1]Shanghai Jiao Tong Univ, Shanghai Chest Hosp, Shanghai Lung Canc Ctr, Shanghai, Peoples R China [2]Huazhong Univ Sci & Technol, Tongji Med Coll, Union Hosp, Wuhan, Peoples R China [3]Shanghai Chest Hosp, Shanghai, Peoples R China [4]Cent South Univ, Canc Hosp, Dept Med Oncol, Changsha, Peoples R China [5]Harbin Med Univ Canc Hosp, Harbin, Peoples R China [6]Shandong First Med Univ & Shandong Acad Med Sci, Shandong Canc Hosp & Inst, Jinan, Peoples R China [7]Xinxiang Med Univ, Affiliated Hosp 1, Xinxiang, Henan, Peoples R China [8]Beijing Canc Hosp, Dept Thorac Med Oncol, Beijing, Peoples R China [9]Linyi Canc Hosp, Linyi, Shandong, Peoples R China [10]Nantong Tumor Hosp, Nantong, Peoples R China [11]Binzhou Med Coll, Affiliated Hosp, Binzhou, Peoples R China [12]Zhengzhou Univ, Affiliated Hosp 1, Zhengzhou, Peoples R China [13]Wenzhou Med Univ, Affiliated Taizhou Hosp, Lab Cellular & Mol Radiat Oncol, Radiat Oncol Inst,Enze Med Hlth Acad, Taizhou, Peoples R China [14]Xinjiang Med Univ, Affiliated Tumor Hosp, Urumqi, Peoples R China [15]Sichuan Canc Hosp, Chengdu, Peoples R China [16]Zhejiang Canc Hosp, Hangzhou, Peoples R China [17]Sun Yat Sen Univ, Dept Thorac Oncol, Affiliated Hosp 5, Zhuhai, Peoples R China [18]Qingdao Univ, Affiliated Hosp, Qingdao, Peoples R China [19]Shandong Canc Hosp & Inst, Jinan, Peoples R China [20]First Hosp Jilin Univ, Changchun, Peoples R China
推荐引用方式(GB/T 7714)：
Lu Shun,Dong Xiaorong,Jian Hong,et al.Randomized phase III trial of aumolertinib (HS-10296, Au) versus gefitinib (G) as first-line treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) and EGFR exon 19 del or L858R mutations (EGFRm).[J].JOURNAL OF CLINICAL ONCOLOGY.2021,39(15):doi:10.1200/JCO.2021.39.15_suppl.9013.
APA：
Lu, Shun,Dong, Xiaorong,Jian, Hong,Chen, Jianhua,Chen, Gongyan...&Cui, Jiuwei.(2021).Randomized phase III trial of aumolertinib (HS-10296, Au) versus gefitinib (G) as first-line treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) and EGFR exon 19 del or L858R mutations (EGFRm)..JOURNAL OF CLINICAL ONCOLOGY,39,(15)
MLA：
Lu, Shun,et al."Randomized phase III trial of aumolertinib (HS-10296, Au) versus gefitinib (G) as first-line treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) and EGFR exon 19 del or L858R mutations (EGFRm).".JOURNAL OF CLINICAL ONCOLOGY 39..15(2021)

资源点击量：43389 今日访问量：0 总访问量：3120 更新日期：2024-09-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 四川省肿瘤医院 技术支持：重庆聚合科技有限公司 地址：成都市人民南路四段55号